R&D at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s R&D?
- ArriVent BioPharma, Inc. (AVBP) reported R&D of $37.62M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s R&D changed year-over-year?
- ArriVent BioPharma, Inc.'s R&D decreased by 38.6% year-over-year, from $61.29M to $37.62M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s R&D?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s R&D has grown at a 53.7% compound annual growth rate (CAGR), from $64.88M to $153.35M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.